JP2009120624A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009120624A5 JP2009120624A5 JP2009058477A JP2009058477A JP2009120624A5 JP 2009120624 A5 JP2009120624 A5 JP 2009120624A5 JP 2009058477 A JP2009058477 A JP 2009058477A JP 2009058477 A JP2009058477 A JP 2009058477A JP 2009120624 A5 JP2009120624 A5 JP 2009120624A5
- Authority
- JP
- Japan
- Prior art keywords
- suspension
- calcium
- atorvastatin hemi
- carried out
- process according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 5
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical group [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25007200P | 2000-11-30 | 2000-11-30 | |
| US26789701P | 2001-02-09 | 2001-02-09 | |
| US28187201P | 2001-04-05 | 2001-04-05 | |
| US31214401P | 2001-08-13 | 2001-08-13 | |
| US32652901P | 2001-10-01 | 2001-10-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002545702A Division JP2004514694A (ja) | 2000-11-30 | 2001-11-29 | アトルバスタチンヘミカルシウムの新規結晶形態およびその調製方法ならびに他の形態の新規調製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009120624A JP2009120624A (ja) | 2009-06-04 |
| JP2009120624A5 true JP2009120624A5 (enExample) | 2010-03-04 |
Family
ID=27540285
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002545702A Pending JP2004514694A (ja) | 2000-11-30 | 2001-11-29 | アトルバスタチンヘミカルシウムの新規結晶形態およびその調製方法ならびに他の形態の新規調製方法 |
| JP2009058477A Pending JP2009120624A (ja) | 2000-11-30 | 2009-03-11 | アトルバスタチンヘミカルシウムの新規結晶形態およびその調製方法ならびに他の形態の新規調製方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002545702A Pending JP2004514694A (ja) | 2000-11-30 | 2001-11-29 | アトルバスタチンヘミカルシウムの新規結晶形態およびその調製方法ならびに他の形態の新規調製方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (15) | US20020183378A1 (enExample) |
| EP (5) | EP1363621A4 (enExample) |
| JP (2) | JP2004514694A (enExample) |
| KR (1) | KR100765871B1 (enExample) |
| CN (1) | CN1489463A (enExample) |
| AU (1) | AU2002217927A1 (enExample) |
| BG (1) | BG107856A (enExample) |
| BR (1) | BR0115892A (enExample) |
| CA (3) | CA2689915A1 (enExample) |
| CZ (1) | CZ20031766A3 (enExample) |
| DE (1) | DE01998348T1 (enExample) |
| ES (2) | ES2215495T1 (enExample) |
| HR (2) | HRP20130545A2 (enExample) |
| HU (1) | HUP0600538A3 (enExample) |
| IL (2) | IL156055A0 (enExample) |
| IS (1) | IS6829A (enExample) |
| MX (1) | MXPA03004844A (enExample) |
| NO (1) | NO20032425L (enExample) |
| PL (1) | PL363228A1 (enExample) |
| SK (1) | SK8062003A3 (enExample) |
| TR (1) | TR200400815T3 (enExample) |
| WO (1) | WO2002043732A1 (enExample) |
| YU (1) | YU42803A (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE36268E (en) * | 1988-03-15 | 1999-08-17 | Boehringer Mannheim Corporation | Method and apparatus for amperometric diagnostic analysis |
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| EP1332130A4 (en) * | 2000-11-03 | 2004-01-21 | Teva Pharma | HEMICALCIC ATORVASTATIN FORM VII |
| AU3289102A (en) * | 2000-11-16 | 2002-06-11 | Teva Pharma | Hydrolysis of (R(R*,R*))-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino) carbonyl)-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| CA2622697A1 (en) * | 2000-12-27 | 2002-07-04 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
| AP1571A (en) * | 2001-06-29 | 2006-02-10 | Warner Lambert Co | Crystalline forms of 'R-(R* ,R*)!-2-(4- fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| CN100471836C (zh) * | 2001-07-30 | 2009-03-25 | 雷迪实验室有限公司 | 托伐他汀钙晶型vi和vii |
| US7074818B2 (en) | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
| NZ529913A (en) * | 2001-08-16 | 2005-03-24 | Teva Pharma | Processes for preparing calcium salt forms of statins |
| CZ296967B6 (cs) * | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
| KR100724515B1 (ko) * | 2002-02-15 | 2007-06-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴 헤미칼슘의 신규한 결정형, 이의 제조 방법 및 아토르바스타틴 헤미칼슘 i형, viii형 및 ix형을 제조하는 신규한 방법 |
| KR20090045420A (ko) * | 2002-02-19 | 2009-05-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화 |
| WO2003099785A1 (en) * | 2002-05-28 | 2003-12-04 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| JP2006503024A (ja) * | 2002-09-03 | 2006-01-26 | モレペン、ラボラトリーズ、リミテッド | Ｖｉ型アトルバスタチンカルシウムまたはその水和物 |
| WO2004050618A2 (en) * | 2002-11-28 | 2004-06-17 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| EP1424324A1 (en) * | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Crystalline form F of Atorvastatin hemi-calcium salt |
| BRPI0410840A (pt) * | 2003-05-30 | 2006-07-04 | Ranbaxy Lab Ltd | derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| ITMI20032144A1 (it) * | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
| CA2456430A1 (en) * | 2004-01-28 | 2005-07-28 | Brantford Chemicals Inc. | Improved process for the preparation of amorphous atorvastatin calcium |
| PL1727795T3 (pl) | 2004-03-17 | 2012-06-29 | Ranbaxy Laboratories Ltd | Sposób wytwarzania soli wapniowej atorwastatyny w formie bezpostaciowej |
| EP2540704B1 (en) | 2004-05-05 | 2019-07-03 | Pfizer Products Inc. | Benethamine salt forms of atorvastatin |
| WO2005115980A1 (en) * | 2004-05-24 | 2005-12-08 | Warner-Lambert Company Llc | Salt forms of atorvastatin |
| RU2412191C2 (ru) * | 2004-07-16 | 2011-02-20 | Лек Фармасьютиклз Д.Д. | Продукты окислительной деструкции кальций аторвастатина |
| US8026376B2 (en) | 2004-07-20 | 2011-09-27 | Pfizer, Inc. | Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoicacid calcium salt (2:1) |
| WO2006012499A2 (en) * | 2004-07-22 | 2006-02-02 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation |
| JP2007512357A (ja) | 2004-09-28 | 2007-05-17 | テバ ファーマシューティカル インダストリーズ リミティド | 不純物を実質的に含まないアトルバスタチンカルシウムの形態を調製するための方法 |
| US20080009540A1 (en) * | 2004-09-30 | 2008-01-10 | Srinivasulu Gudipati | Amorphous Atorvastatin Calcium |
| EP1716114A1 (en) | 2004-10-18 | 2006-11-02 | Teva Pharmaceutical Industries Ltd. | Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent |
| JP2008517992A (ja) | 2004-10-28 | 2008-05-29 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アモルファスのアトルバスタチンを形成する方法 |
| WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
| WO2006054308A2 (en) * | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| DK1698630T3 (da) | 2005-03-03 | 2014-12-08 | Alfa Wassermann Spa | Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater |
| WO2006106372A1 (en) * | 2005-04-08 | 2006-10-12 | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság | New crystalline atorvastatin hemicalcium salt polymorph form |
| US20070032665A1 (en) * | 2005-08-04 | 2007-02-08 | Srinivasulu Gudipati | Preparation of atorvastatin calcium form i |
| ES2270722B1 (es) * | 2005-09-15 | 2008-03-01 | Ercros Industrial, S.A. | Procedimiento para la obtencion de atorvastatina calcica amorfa. |
| US20090216029A1 (en) * | 2005-09-16 | 2009-08-27 | Yatendra Kumar | Process for the production of atorvastatin calcium in amorphous form |
| CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
| KR101329112B1 (ko) | 2005-11-08 | 2013-11-14 | 랜박시 래보러터리스 리미티드 | (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법 |
| US8084488B2 (en) | 2005-11-21 | 2011-12-27 | Pfizer Inc. | Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium |
| EP1808162A1 (en) | 2005-11-21 | 2007-07-18 | Teva Pharmaceutical Industries Ltd. | Atorvastatin pharmaceutical formulation |
| EP1923057A1 (en) | 2005-11-21 | 2008-05-21 | Teva Pharmaceutical Industries Ltd | Atorvastatin pharmaceutical formulation |
| KR20080007561A (ko) | 2005-12-13 | 2008-01-22 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법 |
| EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| JP2007246514A (ja) * | 2006-02-14 | 2007-09-27 | Toyama Chem Co Ltd | ピペラシリンナトリウムの新規な結晶 |
| EP1986997A4 (en) * | 2006-02-22 | 2010-09-15 | Matrix Lab Ltd | NEW CRYSTALLINE HEMI-CALCIUM FORM OF ATORVASTATIN |
| EP1877375A1 (en) * | 2006-03-01 | 2008-01-16 | Teva Pharmaceutical Industries Ltd | Process for preparing a crystalline form of atorvastatin hemi-calcium |
| US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| CN100406438C (zh) * | 2006-06-30 | 2008-07-30 | 浙江新东港药业股份有限公司 | 一种无定型阿伐他汀钙的制备方法 |
| CN101494980A (zh) * | 2006-07-14 | 2009-07-29 | 兰贝克赛实验室有限公司 | HMG-CoA还原酶抑制剂的多晶型形式及其应用 |
| EP2081554A2 (en) * | 2006-09-27 | 2009-07-29 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
| US20100113802A1 (en) * | 2006-11-02 | 2010-05-06 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate |
| US7834195B2 (en) * | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
| AU2008210929A1 (en) * | 2007-01-31 | 2008-08-07 | Toyama Chemical Co., Ltd. | Novel crystal of piperacillin sodium |
| RU2421445C1 (ru) | 2007-03-02 | 2011-06-20 | Донг-А Фарм. Ко., Лтд. | Новые кристаллические формы производных пирролилгептановой кислоты |
| WO2008129562A2 (en) * | 2007-04-20 | 2008-10-30 | Morepen Laboratories Limited | An improved process for the preparation of stable amorphous atorvastatin hemi calcium and their salts thereof |
| CA2694378A1 (en) * | 2007-07-27 | 2009-02-05 | Cipla Limited | Pharmaceutical compositions and process for making them |
| WO2009082362A1 (en) * | 2007-11-05 | 2009-07-02 | Ulkar Kimya San. Ve Tic. A.S. | A method for producing statins in pure form |
| EP2075246A1 (en) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
| CN101538237B (zh) * | 2008-05-30 | 2011-04-06 | 天津和美生物技术有限公司 | 阿伐他汀半钙盐丁酮共结晶物、其制备和作为HMG-CoA酶抑制剂的应用 |
| US8685173B2 (en) | 2008-07-17 | 2014-04-01 | Delaval Holding Ab | Method of cleaning food and beverage manufacturing and handling equipment |
| WO2011028309A1 (en) | 2009-09-04 | 2011-03-10 | University Of Toledo | PROCESSES FOR PRODUCING OPTICALLY PURE β-LACTONES FROM ALDEHYDES AND COMPOSITIONS PRODUCED THEREBY |
| US11473032B2 (en) | 2010-02-02 | 2022-10-18 | Fuchs Petrolub Se | Constant velocity joint having a boot |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| CN102766136A (zh) * | 2012-08-07 | 2012-11-07 | 浙江宏元药业有限公司 | 一种制备阿托伐他汀钙中间体的方法 |
| SG10202012791TA (en) | 2013-11-15 | 2021-01-28 | Akebia Therapeutics Inc | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| CN105111123A (zh) * | 2013-11-25 | 2015-12-02 | 李兴惠 | 阿托伐他汀钙及组合物 |
| CN104945300B (zh) * | 2015-06-17 | 2017-05-10 | 北京嘉林药业股份有限公司 | 一种ⅰ型阿托伐他汀钙的纯化方法 |
| CN104983690A (zh) * | 2015-08-18 | 2015-10-21 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗冠心病的药物阿托伐他汀钙组合物干混悬剂 |
| EP3272336A1 (de) * | 2016-07-19 | 2018-01-24 | Stada Arzneimittel Ag | Atorvastatin-zusammensetzung |
| WO2025147589A1 (en) | 2024-01-05 | 2025-07-10 | Osanni Bio, Inc. | Implants, compositions, and methods for treating retinal diseases and disorders |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US115709A (en) * | 1871-06-06 | Improvement in curriers slickers | ||
| US99224A (en) * | 1870-01-25 | Improvement in pocket-sates for friction-matches | ||
| US2598627A (en) * | 1949-10-11 | 1952-05-27 | Robert Gair Co Inc | Folding carton |
| DE2748825C2 (de) * | 1976-11-02 | 1986-11-27 | Sankyo Co., Ltd., Tokio/Tokyo | Substituierte 3,5-Dihydroxyheptansäurederivate und diese enthaltende Arzneimittel gegen Hyperlipämie |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| WO1994016693A1 (en) * | 1993-01-19 | 1994-08-04 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
| US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| DE4411536A1 (de) * | 1994-04-02 | 1995-10-05 | Cassella Ag | Wasserquellbare hydrophile Polymere |
| ES2167587T3 (es) * | 1995-07-17 | 2002-05-16 | Warner Lambert Co | Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina). |
| HRP960312B1 (en) | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| US6065729A (en) * | 1998-01-28 | 2000-05-23 | Prince Corporation | Slide-out container holder |
| US5959156A (en) | 1998-11-12 | 1999-09-28 | Bp Amoco Corporation | Preparation of polyoxymethylene dimethyl ethers by catalytic conversion of dimethyl ether with formaldehyde formed by oxy-dehydrogenation of dimethyl ether |
| IN191236B (enExample) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
| HU226640B1 (en) * | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
| EP1535613B1 (en) * | 1999-11-17 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Process for preparing a polymorphic form of atorvastatin calcium |
| US7411075B1 (en) * | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| IL149088A0 (en) * | 1999-12-17 | 2002-11-10 | Warner Lambert Res & Dev Ie | A process for producing crystalline atorvastatin calcium |
| DE60024133T2 (de) | 1999-12-17 | 2006-08-03 | Pfizer Science And Technology Ireland Ltd., Dun Laoghaire | Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form |
| EP1332130A4 (en) * | 2000-11-03 | 2004-01-21 | Teva Pharma | HEMICALCIC ATORVASTATIN FORM VII |
| AU3289102A (en) * | 2000-11-16 | 2002-06-11 | Teva Pharma | Hydrolysis of (R(R*,R*))-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino) carbonyl)-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| CA2622697A1 (en) * | 2000-12-27 | 2002-07-04 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
| US6476235B2 (en) | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
| WO2002057228A1 (en) | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| IN190564B (enExample) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| AP1571A (en) | 2001-06-29 | 2006-02-10 | Warner Lambert Co | Crystalline forms of 'R-(R* ,R*)!-2-(4- fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| CN100471836C (zh) | 2001-07-30 | 2009-03-25 | 雷迪实验室有限公司 | 托伐他汀钙晶型vi和vii |
| US7074818B2 (en) * | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
| NZ529913A (en) * | 2001-08-16 | 2005-03-24 | Teva Pharma | Processes for preparing calcium salt forms of statins |
| US7563911B2 (en) | 2001-08-31 | 2009-07-21 | Morepen Laboratories Ltd. | Process for the preparation of amorphous atorvastin calcium salt (2:1) |
| AU2002368026B2 (en) | 2001-11-30 | 2007-12-06 | University Of Maryland, Baltimore | Novel proteins in enteroaggregative Escherichia coli (EAEC) useful for diagnosis and therapy of EAEC infections |
| UA77990C2 (en) | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| KR100724515B1 (ko) | 2002-02-15 | 2007-06-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴 헤미칼슘의 신규한 결정형, 이의 제조 방법 및 아토르바스타틴 헤미칼슘 i형, viii형 및 ix형을 제조하는 신규한 방법 |
| KR20090045420A (ko) | 2002-02-19 | 2009-05-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화 |
| JP4364650B2 (ja) | 2002-03-28 | 2009-11-18 | イーエムシー コーポレイション | データ記憶システム |
| WO2003099785A1 (en) * | 2002-05-28 | 2003-12-04 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| JP2006503024A (ja) | 2002-09-03 | 2006-01-26 | モレペン、ラボラトリーズ、リミテッド | Ｖｉ型アトルバスタチンカルシウムまたはその水和物 |
| SI21302A (sl) | 2002-10-11 | 2004-04-30 | LEK farmacevtska dru�ba d.d. | Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino |
| EP1424324A1 (en) | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Crystalline form F of Atorvastatin hemi-calcium salt |
| WO2004050618A2 (en) | 2002-11-28 | 2004-06-17 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| US20040242670A1 (en) * | 2003-06-02 | 2004-12-02 | Sonny Sebastian | Process for preparation of amorphous atorvastatin calcium |
| WO2006012499A2 (en) * | 2004-07-22 | 2006-02-02 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation |
| EP1716114A1 (en) * | 2004-10-18 | 2006-11-02 | Teva Pharmaceutical Industries Ltd. | Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent |
| US20070032665A1 (en) * | 2005-08-04 | 2007-02-08 | Srinivasulu Gudipati | Preparation of atorvastatin calcium form i |
-
2001
- 2001-10-29 IL IL15605501A patent/IL156055A0/xx unknown
- 2001-11-29 ES ES01998348T patent/ES2215495T1/es active Pending
- 2001-11-29 EP EP01998348A patent/EP1363621A4/en not_active Ceased
- 2001-11-29 SK SK806-2003A patent/SK8062003A3/sk unknown
- 2001-11-29 PL PL01363228A patent/PL363228A1/xx not_active Application Discontinuation
- 2001-11-29 EP EP10151205.1A patent/EP2192112B1/en not_active Expired - Lifetime
- 2001-11-29 WO PCT/US2001/044636 patent/WO2002043732A1/en not_active Ceased
- 2001-11-29 TR TR2004/00815T patent/TR200400815T3/xx unknown
- 2001-11-29 HU HU0600538A patent/HUP0600538A3/hu unknown
- 2001-11-29 DE DE0001363621T patent/DE01998348T1/de active Pending
- 2001-11-29 EP EP10152443A patent/EP2192113A1/en not_active Withdrawn
- 2001-11-29 CA CA2689915A patent/CA2689915A1/en not_active Abandoned
- 2001-11-29 KR KR1020037007298A patent/KR100765871B1/ko not_active Expired - Fee Related
- 2001-11-29 HR HRP20130545AA patent/HRP20130545A2/hr not_active Application Discontinuation
- 2001-11-29 CZ CZ20031766A patent/CZ20031766A3/cs unknown
- 2001-11-29 HR HR20030523A patent/HRP20030523A2/hr not_active Application Discontinuation
- 2001-11-29 CN CNA018223400A patent/CN1489463A/zh active Pending
- 2001-11-29 CA CA002625277A patent/CA2625277A1/en not_active Abandoned
- 2001-11-29 US US09/997,126 patent/US20020183378A1/en not_active Abandoned
- 2001-11-29 BR BR0115892-9A patent/BR0115892A/pt not_active IP Right Cessation
- 2001-11-29 AU AU2002217927A patent/AU2002217927A1/en not_active Abandoned
- 2001-11-29 JP JP2002545702A patent/JP2004514694A/ja active Pending
- 2001-11-29 EP EP06024449A patent/EP1783113A3/en not_active Ceased
- 2001-11-29 EP EP10151206A patent/EP2194041A1/en not_active Withdrawn
- 2001-11-29 MX MXPA03004844A patent/MXPA03004844A/es active IP Right Grant
- 2001-11-29 YU YU42803A patent/YU42803A/sh unknown
- 2001-11-29 ES ES10151205.1T patent/ES2437157T3/es not_active Expired - Lifetime
- 2001-11-29 CA CA002429590A patent/CA2429590C/en not_active Expired - Fee Related
-
2003
- 2003-05-21 IL IL156055A patent/IL156055A/en not_active IP Right Cessation
- 2003-05-27 IS IS6829A patent/IS6829A/is unknown
- 2003-05-28 NO NO20032425A patent/NO20032425L/no not_active Application Discontinuation
- 2003-05-29 BG BG107856A patent/BG107856A/xx unknown
-
2004
- 2004-07-28 US US10/901,845 patent/US6992194B2/en not_active Expired - Fee Related
- 2004-11-19 US US10/994,142 patent/US7144916B2/en not_active Expired - Fee Related
-
2005
- 2005-07-29 US US11/193,089 patent/US7256212B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/192,672 patent/US7161012B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/192,674 patent/US7456297B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/192,707 patent/US7151183B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/193,112 patent/US7189861B2/en not_active Expired - Fee Related
- 2005-10-24 US US11/257,815 patent/US20060106232A1/en not_active Abandoned
- 2005-10-24 US US11/257,979 patent/US7468444B2/en not_active Expired - Fee Related
- 2005-10-24 US US11/257,886 patent/US20060100267A1/en not_active Abandoned
- 2005-10-24 US US11/257,821 patent/US7342120B2/en not_active Expired - Fee Related
- 2005-10-24 US US11/257,828 patent/US7488750B2/en not_active Expired - Fee Related
- 2005-10-24 US US11/257,808 patent/US20060106231A1/en not_active Abandoned
-
2007
- 2007-10-23 US US11/977,387 patent/US20080214650A1/en not_active Abandoned
-
2009
- 2009-03-11 JP JP2009058477A patent/JP2009120624A/ja active Pending